^
Association details:
| Biomarker: | AR-V7 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | onvansertib (PCM-075) (PLK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Study of the Polo-like kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with Abiraterone in Patients with Abiraterone (Abi)-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published date:
10/07/2020
Excerpt:
Onvansertib showed efficacy in patients with AR alterations [N = 8; AR-V7 (6)...3/8 (37%) achieved DC, 4 had SD, of whom 3 had durable SD (range 7 9mos)….Abi/prednisone + onvansertib is well tolerated and AE’s are effectively managed.
Secondary therapy:
prednisone + AST-2970
Trial ID:
